Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients

Clinical Lung Cancer

Volumn 12, Issue 5, 2011, Pages 320-327

  Jantus Lewintre, Eloisa ^a   Sirera, Rafael ^b   Cabrera, Andrea ^a   Blasco, Ana ^a   Caballero, Cristina ^a   Iranzo, Vega ^a   Rosell, Rafael ^c   Camps, Carlos ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Biomarker; EGFR prognostic; NSCLC

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNCTIONAL STATUS; GENDER; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 80052495034     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.031     Document Type: Article

References (36)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. C.L. Arteaga Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 suppl 4 2002 31 39 (Pubitemid 34977161)
3. M.A. Olayioye, R.M. Neve, and H.A. Lane The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J 19 2000 3159 3167 (Pubitemid 30428195)
4. F. Ciardiello, and G. Tortora A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clin Cancer Res 7 2001 2958 2970 (Pubitemid 32963812)
5. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137 (Pubitemid 33674041)
6. D. Veale, N. Kerr, and G.J. Gibson The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival Br J Cancer 68 1993 162 165 (Pubitemid 23178571)
7. V. Rusch, D. Klimstra, and E. Venkatraman Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression Clin Cancer Res 3 1997 515 522 (Pubitemid 27211827)
8. F.R. Hirsch, M. Varella-Garcia, and P.A. Bunn Jr Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 2003 3798 3807 (Pubitemid 46606235)
9. C. Rao, Q. Hu, and J. Ma Comparison of the epidermal growth factor receptor protein expression between primary non-small cell lung cancer and paired lymph node metastases: implications for targeted nuclide radiotherapy J Exp Clin Cancer Res 29 2010 7
10. H.S. Kim, Y.H. Park, and J. Lee Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray Cancer 116 2010 676 685
11. G. Selvaggi, S. Novello, and V. Torri Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer Ann.Oncol 15 2004 28 32 (Pubitemid 38139599)
12. J. Brabender, K.D. Danenberg, and R. Metzger Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival Clin Cancer Res 7 2001 1850 1855 (Pubitemid 32994816)
13. T.A. D'Amico, M. Massey, and J.E. Herndon A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers J Thorac Cardiovasc Surg 117 1999 736 743 (Pubitemid 29163078)
14. U. Pastorino, S. Andreola, and E. Tagliabue Immunocytochemical markers in stage I lung cancer: relevance to prognosis J Clin Oncol 15 1997 2858 2865 (Pubitemid 27330013)
15. A.P. Meert, B. Martin, and P. Delmotte The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis Eur Respir J 20 2002 975 981 (Pubitemid 35175137)
16. R. Partanen, K. Hemminki, and H. Koskinen The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients J Occup Med 36 1994 1324 1328
17. A.T. Baron, J.A. Wilken, and D.E. Haggstrom Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer IDrugs 12 2009 302 308
18. A. Ciledag, A. Kaya, and O. Yetkin The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer Tuberk Toraks 56 2008 390 395
19. W. Jacot, J.L. Pujol, and J.M. Boher Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer Br J Cancer 91 2004 430 433 (Pubitemid 39093559)
20. M.T. Sandri, H.A. Johansson, and L. Zorzino Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy Cancer 110 2007 509 517 (Pubitemid 47106138)
21. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
22. J.L. Reiter, D.W. Threadgill, and G.D. Eley Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms Genomics 71 2001 1 20 (Pubitemid 32097198)
23. A.T. Baron, E.M. Cora, and J.M. Lafky Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer Cancer Epidemiol Biomarkers Prev 12 2003 103-3
24. M. Perez-Torres, B.L. Valle, and N.J. Maihle Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells Exp Cell Res 314 2008 2907 2918
25. H. Sasaki, H. Yukiue, and K. Mizuno Elevated serum epidermal growth factor receptor level is correlated with lymph node metastasis in lung cancer Int J Clin Oncol 8 2003 79 82 (Pubitemid 36548475)
26. I. Abdel Salam, H.E. Gaballa, and N. Abdel Wahab Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation Med Oncol 26 2009 161 166
27. V. Muller, I. Witzel, and K. Pantel Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer Anticancer Res 26 2006 1479 1487
28. A.T. Baron, C.H. Boardman, and J.M. Lafky Soluble epidermal growth factor receptor (SEG-FR) and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer Cancer Epidemiol Biomarkers Prev 14 2005 306 318 (Pubitemid 40270090)
29. P.A. Kavsak, H. Hirte, and S.J. Hotte Vascular endothelial growth factor concentration as a predictive marker: ready for primetime? Clin Cancer Res 16 2010 1341
30. P.A. Kavsak, A. Lee, and H. Hirte Cytokine elevations in acute coronary syndrome and ovarian cancer: a mechanism for the up-regulation of the acute phase proteins in these different disease etiologies Clin Biochem 41 2008 607 610
31. W. Jelkmann Pitfalls in the measurement of circulating vascular endothelial growth factor Clin Chem 47 2001 617 623 (Pubitemid 32275802)
32. C. Souder, K. Leitzel, and S.M. Ali Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer Cancer 107 2006 2337 2345 (Pubitemid 44753823)
33. R. Gaafar, A. Bahnassy, and I. Abdelsalam Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma Lung Cancer 70 2010 43 50
34. M.J. Oh, J.H. Choi, and Y.H. Lee Mutant p53 protein in the serum of patients with cervical carcinoma: correlation with the level of serum epidermal growth factor receptor and prognostic significance Cancer Lett 203 2004 107 112 (Pubitemid 37506090)
35. V. Gregorc, G.L. Ceresoli, and I. Floriani Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer Clin Cancer Res 10 2004 6006 6012 (Pubitemid 39287505)
36. A. Basu, M. Raghunath, and S. Bishayee Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation Mol Cell Biol 9 1989 671 677 (Pubitemid 19038870)